Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2023-06-02 00:00:00 ET · period of report 2023-05-31 · accession 0001787306-23-000062 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-02 | 2023-05-31 | ARQT | Heron Patrick J | Dir, 10% | A - Grant | $0.00 | +4,375 | 8,687 | +101% | $0 |
| D | 2023-06-02 | 2023-05-31 | ARQT | Heron Patrick J | Dir, 10% | A - Grant | $0.00 | +12.2K | 12.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-31 | A | A | 4,375 | $0.00 | 8,687 | D | — | — | (F1) Includes 4,375 Restricted Stock Units (?RSUs?). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. |
| 2 | Derivative | Stock Option (right to buy) | 2023-05-31 | A | A | 12,220 | $0.00 | 12,220 | D | $7.51 · — to 2033-05-31 | 12,220 Common Stock | (F2) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023. |